854056-07-8
854056-07-8 結構式
基本信息
羅哌卡因甲磺酸鹽
甲磺酸羅哌卡因中間體
甲磺酸羅哌卡因854056-07-8
N-(2,6-二甲基苯基)-1-丙基哌啶-2-甲酰胺甲磺酸鹽
N-(2,6-二甲基苯基)-1-正丙基哌啶-2-甲酰胺甲磺酸鹽
S-(-)-N-(2,6-二甲基苯基)-1-丙基-2-哌啶甲酰胺甲磺酸鹽
Ropivacaine Mesylate API
Ropivacaine mesylate USP/EP/BP
Ropivacaine Mesylate Injection
(2S)-N-(2,6-Dimethylphenyl)-1-propyl-2-piperidinecarboxamide monomethanesulfonate
Ropivacaine mesylate (2S)-N-(2,6-Dimethylphenyl)-1-propyl-2-piperidinecarboxamide monomethanesulfonate
物理化學性質
常見問題列表
圖1為甲磺酸羅哌卡因注射液
有關甲磺酸羅哌卡因的概述、藥理作用、臨床應用是由Chemicalbook的丁紅編輯整理。（2015-12-02）
2.硬膜外阻滯。
3.外周神經阻滯。
4.蜘網膜下腔阻滯。
5.局部靜脈麻醉。
6.術后鎮(zhèn)痛。
7.產科麻醉。
8.分娩鎮(zhèn)痛。
IC50: sodium ion influxIC50: 402.7 μM (TREK-1 in COS-7 cell's membrane)
Epidural administration of Ropivacaine mesylate effectively blocks neuropathic pain (both mechanical allodynia and heat hyperalgesia) without induction of analgesic tolerance and significantly delays the development of neuropathic pain produced by peripheral nerve injury.
Ropivacaine mesylate inhibits pressure-induced increases in filtration coefficient (Kf) without affecting pulmonary artery pressure (Ppa), pulmonary capillary pressures (Ppc), and zonal characteristics (ZC).
Ropivacaine mesylate prevents pressure-induced lung edema and associated hyperpermeability as evidence by maintaining PaO2, lung wet-to-dry ratio and plasma volume in levels similar to sham rats.
Ropivacaine mesylate inhibits pressure-induced NO production as evidenced by decreased lung nitro-tyrosine content when compared to hypertensive lungs.
| Animal Model: | Adult Sprague-Dawley rats (300-400g) |
| Dosage: | 1 μM |
| Administration: | Infusion (added to the perfusate reservoir) |
| Result: | Attenuated pressure-dependent increases in filtration coefficient (K f ). |